Your browser doesn't support javascript.
loading
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich, K; Puig, L; Szepietowski, J C; Paul, C; Lacour, J P; Tsianakas, A; Sieder, C; Rissler, M; Pournara, E; Orsenigo, R.
Affiliation
  • Reich K; Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Skinflammation® Center, Hamburg, Germany.
  • Puig L; Dermatologikum Berlin, Berlin, Germany.
  • Szepietowski JC; Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Paul C; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
  • Lacour JP; Department of Dermatology, Toulouse University and Larrey Hospital, Toulouse, France.
  • Tsianakas A; Hôpital Archet, CHU de Nice, Nice, France.
  • Sieder C; University of Münster, Münster, Germany.
  • Rissler M; Novartis Pharma GmbH, Nuremberg, Germany.
  • Pournara E; Novartis Pharma AG, Basel, Switzerland.
  • Orsenigo R; Novartis Pharma AG, Basel, Switzerland.
Br J Dermatol ; 182(2): 304-315, 2020 02.
Article in En | MEDLINE | ID: mdl-31102257
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Dermatol Year: 2020 Document type: Article Affiliation country: Germany Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Dermatol Year: 2020 Document type: Article Affiliation country: Germany Country of publication: United kingdom